In this episode Dr Harry Gibbs, from The Alfred Hospital in Victoria and Dr Ander Cohen from Guy’s and St Thomas’ Hospital, King’s College in London, UK talk about the management of patients on therapy who have an ischaemic stroke. They talk about potential causes of stroke – whether the stroke may be medication related or unrelated to medication, and when it is safe to restart anticoagulation.

ELIQUIS® (apixaban)

PBS Information: Authority required (STREAMLINED) Refer to PBS Schedule for full authority information.

PBS Codes: NVAF – 4269 and DVT/Pe initial treatment – 4298 (DVT); 5098 (PE). Other PBS codes differ – please refer to PBS Schedule.

NVAF: Non-valvular atrial fibrillation; DVT: Deep vein thrombosis; PE: Pulmonary embolism.

Before prescribing, please review full ELIQUIS Product Information available from Bristol Myers Squibb Australia by calling 1800 067 567

Please note that in the Aristotle study, patients were excluded if they had experienced an ischaamic stroke within the previous 7 days. There are limited data on the timing of restarting anticoagulation post stroke. 

ELIQUIS Consumer Medical Information

ELIQUIS Product Information

References

1. Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-92.

2. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-67.

 t360 is an educational program supported by Bristol Myers Squibb Australia Pty Ltd, ABN 33 004 333 322, Level 2, 4 Nexus Court, Mulgrave VIC 3170 and Pfizer Australia Pty Ltd, ABN 50 008 422 348, 151 Clarence Street, Level 15–18, Sydney NSW 2000, and developed by Elixir Healthcare Education Pty Limited, ABN 36 092 185 665, Level 32, 101 Miller Street, North Sydney NSW 2060. ©Copyright 2022 Bristol Myers Squibb–Pfizer Alliance and Elixir Healthcare Education Pty Limited. PP-ELI-AUS-1096.